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ABSTRACT
Objective: To describe the frequency of depression in patients with hepatitis C (HCV) and relate 
to the biological variables and liver function. Methods: cross-sectional, descriptive study with a 
quantitative approach, which assessed depression using the criteria of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V) and the association with biological and liver function variables 
in 85 patients HCV chronically infected indicated for direct-acting antiviral therapy (DAA) between 
May 2018 and May 2019. Results: depression was detected in 47.1% of patients, predominantly mild 
depression (95%). However, depression occurred independently of biological characteristics, such 
as gender, age, education, associated comorbidities and liver function, such as degree of fibrosis and 
viral genotype. Conclusions: the frequency of depression was high in patients with HCV and had no 
statistical relationship with biological characteristics and liver function, suggesting that active search 
for depression could be a valuable strategy in managing these patients.
Descriptors: Depression, Hepatitis C, DSM-V, Chronic hepatitis C. 
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RESUMO
Objetivo: Descrever a frequência de depressão em pacientes com hepatite C 
(HCV) e relacionar com as variáveis biológicas e função hepática. Métodos: 
estudo transversal, descritivo, de abordagem quantitativa, que avaliou a 
depressão utilizando os critérios do Manual de diagnóstico e estatístico de 
transtornos mentais (DSM-V) e a associação com as variáveis biológicas 
e de função hepática em 85 pacientes com HCV crônica indicados para a 
terapia antiviral de ação direta (DAA) entre maio de 2018 e 2019. Resultados: 
detectou-se depressão em 47,1% dos pacientes, predominantemente 
depressão leve (95%). Entretanto a depressão ocorreu de forma independente 
das características biológicas, como sexo, idade, escolaridade, comorbidades 
associadas e da função hepática, como grau de fibrose e genótipo viral. 
Conclusões: a frequência de depressão foi alta em pacientes com HCV 
e não teve relação estatística com as características biológicas e função 
hepática, sugerindo a busca ativa da depressão como estratégia na condução 
destes pacientes. 
Descritores: Depressão, Hepatite, DSM-V, Hepatite C crônica.
RESUMEN
Objetivo: Describir la frecuencia de depresión en pacientes con hepatitis C 
(VHC) y relacionarla con variables biológicas y función hepática. Métodos: 
estudio descriptivo transversal con abordaje cuantitativo, que evaluó la 
depresión utilizando los criterios del Manual Diagnóstico y Estadístico de 
los Trastornos Mentales (DSM-V) y la asociación con variables biológicas 
y de función hepática en 85 pacientes con VHC crónico indicados para 
tratamento com terapia antiviral de acción directo (AAD) entre mayo de 
2018 y 2019. Resultados: se detectó depresión en el 47,1% de los pacientes, 
predominantemente depresión leve (95%). Sin embargo, la depresión se 
produjo independientemente de las características biológicas, como el sexo, 
la edad, la educación, las comorbilidades asociadas y la función hepática, 
como el grado de fibrosis y el genotipo viral. Conclusiones: la frecuencia 
de depresión fue alta en pacientes con VHC y no tuvo relación estadística 
con características biológicas y función hepática, sugiriendo la búsqueda 
activa de depresión como estrategia en el manejo de estos pacientes
Descriptores: Depresión, Hepatitis C, DSM-V, Hepatitis C crónica.
INTRODUCTION
It is estimated that around 71 million people are 
infected with the hepatitis C virus (HCV) worldwide, 
and approximately 400 thousand die each year due to 
complications of this disease. In Brazil, the number of 
people chronically infected with HCV is estimated to be 
around 650,000. The highest detection rates have been 
observed in males, with a reduction in the sex ratio over 
the years.1-2 Neuropsychological and neurocognitive 
impairment are frequently reported by patients with 
chronic HCV infection. These changes occur regardless 
of HCV genotype and even in the absence of structural 
brain damage. According to epidemiological studies, about 
one-third of chronically HCV-infected individuals have 
depression, which represents a frequency 1.5 to 4 times 
higher compared to depression alone. 3-5
Depression is a serious and highly prevalent medical 
problem throughout the population. According to the 
World Health Organization (WHO), the prevalence of 
depression in the primary health care network is 10.4%, 
either alone or associated with a physical disorder. It ranks 
fourth among the main causes of burden, accounting for 
4.4% of the burden of disease during life. It ranks first 
when considering time lived with disability over a lifetime 
(11.9%) and is the leading cause of disability, with more 
than 300 million people suffering from this condition.4
Depression in HCV used to be related to symptoms 
induced by Interferon (IFN) treatment, but has regained 
prominence with the new drug therapies, the direct-
acting antivirals (DAA), as depression rates have remained 
high (20-50%) after their implementation. Therefore, 
understanding and diagnosing depression are still crucial 
points in the DAA era.5-6 Even in the face of this reality, 
the search for and treatment of depression in HCV patients 
is not routinely practiced, leading to impairments in 
treatment adherence, functionality, and quality of life.2 
Studies of groups with nurses administering medications, 
of multidisciplinary interventions, and of programs 
incorporating cognitive-behavioral therapy have improved 
adherence to treatment and depressive symptoms with 
simultaneous improvement in sustained virologic response 
(SVR).7-9 In addition to mood disorders, low education, 
common in patients in the public health network, also 
interferes in adherence to treatment of HCV and other 
chronic comorbidities, as it limits the understanding of the 
treatment. 2-3 
In HCV patients, depression can be directly related 
to the viral infection or be a comorbidity, and it becomes 
opportune to diagnose it regardless of the cause and 
effect relationship in HCV patients. The high prevalence 
of depression, both in Brazil and worldwide, in these 
patients raises questions about characteristics that can be 
considered risk and protection factors for the development 
of this disease.2,4,10-12          
Thus, this study aims to describe the frequency of 
depression in patients with hepatitis C (HCV) and relate it 
to biological variables and liver function.  This work is part 
of the research project developed in the Hepatology service 
of HUGG and becomes even more important, since it is an 
opinion-forming university hospital that intends to benefit 
patients and the service.
METHODS
This is a cross-sectional, descriptive study with a 
quantitative approach. Data were collected during the 
consultation prior to HCV treatment with DAA in the 
period from May 2018 to May 2019 at HUGG, located in 
the Tijuca neighborhood, northern zone of Rio de Janeiro, 
RJ, Brazil. The gastroenterology and hepatology service has 
accreditation from the Ministry of Health to act as an HCV 
treatment center. The pre-treatment consultation was used 
as a strategy to ensure evaluation just before the start of 
therapy and try to ensure follow-up and reassessment with 
adequate follow-up in the service. 
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Patients were included in the research: duly registered 
in the gastroenterology and hepatology outpatient clinic 
of HUGG; with confirmed diagnosis of chronic HCV 
infection (with Anti-HCV reagent for more than six months 
and confirmed with HCV-RNA detectable for more than 
six months), even if coinfected by HIV; patients who fit the 
DAA therapy protocol, according to the recommendations 
of the Clinical Protocol and Therapeutic Guidelines (PCDT) 
for Hepatitis C and co-infections of the Ministry of Health 
, which are part of a national list forwarded to the Ministry 
of Health and had their medications released during the 
research period. Patients coinfected with hepatitis B and 
acute HCV were excluded. 
To diagnose depression, the criteria of the Diagnostic 
and Statistical Manual of Mental Disorders in its fifth 
edition (DSM-V) were used, and then, in patients with 
depression, the Hamilton scale was applied as a screening 
to classify depression into mild (score between 7 and 17), 
moderate (score between 18 and 24), or severe (above 25 
points). In addition, all patients answered a data collection 
questionnaire with the following information: sex, age, 
educational level, religion, comorbidities, medications 
in use, route of infection, HCV genotype and viral load, 
degree of liver fibrosis, liver function (modified Child-
Pugh grading scale for prognostic evaluation). Education 
was divided by the length of study into equal or greater 
than eight years (≥ 8 years) and less than eight years (< 8 
years) of study.
All data were tabulated in Excel® 2013 spreadsheet and 
for statistical analysis we used BioStat 5.3® and Prism 5. 
We used descriptive statistics with the absolute number 
and percentage of patients for categorical variables and 
the mean for continuous variables. We used Fisher's 
exact test or Chi-square to test the association between 
variables. This work is part of the research project "Global 
and cognitive assessment in elderly people with hepatitis 
C virus infection before and after treatment with DAA 
regimen", approved by the Research Ethics Committee of 
the Gaffree and Guinle University Hospital of HUGG on 
May 30, 2019, under CAAE: 12630419.0.0000.5258 and 
opinion 3.358.238. All participants signed the Informed 
Consent Form (ICF).
RESULTS
In a previous study, our group evaluated the cognitive 
impairment caused by HCV in the 85 participants of this 
study, whose main biological characteristics have already 
been described.10 Briefly, the mean age of the patients 
was 58.1 years, 50 (58.8%) were female, and 60 (70.6%) 
had studied 8 or more years. The predominant genotype 
was type 1 (93%), with a mean viral load of 112,298 copies 
and considered compensated in the disease prognostic 
classification (Child A; 95.3%). Depression was diagnosed 
in 40 (47.1%) patients, of whom 38 (95%) had mild 
depression, according to the Hamilton score, and two (5%) 
had moderate depression.
Next, an association between depression and the 
biological variables of the study participants was sought. 
The variables age, sex, and ethnicity were equally distributed 
between the groups with and without depression, as were 
education and religion (Table 1). The analysis of lifestyle-
related variables and the presence of other diseases revealed 
that sedentary patients with multiple comorbidities 
and those who used more than three medications 
predominated, however, it was not possible to observe a 
statistical association with depression, Table 1.
Table 1- Association of  biological variables and depression.
Assessing the depressive episodes and correlating 
them to the degree of hepatic fibrosis, half of the patients 
with F0-F1 and F4 and close to 45% of the patients in 
F2 and F3 presented depression, and no association was 
observed between the degree of fibrosis nor the Child-
Pugh prognostic scale, Table 1. Finally, relating the cases 
of depression found in the sample to HCV genotypes, 
genotypes 1A/1B and 1 had more than 50% of patients with 
depression, genotypes 1A and 1B between 30% and 50%, 
and the patient with genotype 4 had no depression, (Table 
1). No association was observed between the variables 
depression and HCV genotype (p = 0.4332), Table 1, not 
even when we analyzed only genotypes 1, 1A and 1B, the 
most prevalent genotypes in the population (p = 0.445). 
DISCUSSION
The present study sought to describe the prevalence of 
depression in patients with HCV treated at HUGG and to 
search for an association between depression and social 
and biological factors. Almost half of the patients presented 
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symptoms of depression, corroborating the findings of 
other studies that reveal a prevalence that varies between 
20 and 50% in patients with HCV, while the prevalence in 
the general population is around 10%.1,4,11-13 The frequency 
of depression was high in our study in the pre-treatment 
period, reinforcing that the active search for depression 
should be part of the care routine. It is believed that the 
high rate of mild depression and the low rates of moderate 
and severe depression are due to the fact that many patients 
are looking forward to the opportunity to start treatment 
with AADs and the possibility of a cure.14-15 
In São Paulo, researchers followed 58 HCV patients 
before and after treatment with DAAs. The data from 
the pre-treatment evaluation are similar to those found 
in our population, that is, high rates of depression and 
neurocognitive alterations, however, the post-treatment 
analysis of the São Paulo group shows significant 
improvement of some neurocognitive symptoms in patients 
who achieved HCV eradication, but the frequency of 
depressive symptoms did not show a statistically significant 
decrease.16 As the interface of psychic and cognitive 
symptoms is a frequent and relevant situation in clinical 
practice, the improvement of neurocognitive symptoms 
without improvement of depressive symptoms should be 
highlighted, because the evaluation of these symptoms 
with integrated tests is important and should be stimulated 
aiming at improving quality of life during and after HCV 
infection.10,17
The average age found is as expected, since it follows 
the statistical data from Brazil and the world. It speaks in 
favor of the length of the disease, which is long, and the 
chronicity of HCV, where patients are submitted to risk 
factors for depression, which include social stigma and 
negative expectations about the prognosis.1,3,8,18 
In the general population, females are more affected 
by depression in a 2:1 ratio. Here, we found no statistically 
significant difference between men and women, which 
differs from the literature, and we can postulate that the 
direct action of the virus on the central nervous system 
is the main explanation, which reinforces that regardless 
of gender, the search for a diagnosis of depression is 
fundamental.1,19  
The occurrence of depression is strongly associated 
with social and economic indicators, such as low income 
and education levels. It was expected that the high level of 
education in this population would be a protective factor, 
but this did not happen. It is possible that some biological 
factors, such as the HCV inflammatory-infectious process 
and chronicity are more relevant for the outcome than 
those analyzed here.11,18
The analysis of viral characteristics showed that in 
this research, the absolute majority had genotype 1, the 
most prevalent in Brazil and worldwide, and similar to 
other studies, the cases of depression were not related 
to genotype.1,2,16 The high viral load was expected in this 
population, because all patients were awaiting the release of 
DAAs by the Brazilian Ministry of Health, according to the 
national protocol.1-2,20-21
The number of comorbidities and sedentary lifestyle 
are expected for the average age of the population.22 
Although we did not find a statistical association with 
depression, these variables may impair the interpretation of 
neuropsychological tests, since the symptoms of depression 
may be linked to another disease, demonstrating once again 
the importance of depression screening and the need to 
develop studies that seek to elucidate these interactions.23 
The degree of fibrosis also had an equitable distribution 
between patients with and without depression, indicating 
that liver dysfunction did not impair the evaluation. 
The results of the Child-Pugh scale reinforce this idea, 
since with most patients in Child A5 and it is clear that 
encephalopathy did not interfere with these results and 
shows that depressive symptoms were independent of the 
degree of fibrosis.12-13,19,23
The descriptive design, cross-sectionality, and small 
number of subjects limit the understanding of causality 
between depression and HCV, as well as the generalization 
of these data to the entire population. Even so, our 
data resemble the literature on the topic, presenting a 
high prevalence of depression in patients with HCV, 
strengthening the idea that one cannot ignore the high 
rates of depression in patients with chronic HCV because 
it can negatively interfere in the quality of life and in the 
outcomes of the disease and that the development of 
more studies that seek to understand the cause and effect 
relationship of these diseases should be encouraged.
CONCLUSIONS
Our results show that the frequency of depression is high 
in patients with HCV. We also highlight that the frequency 
of depression was independent of gender, education, HCV 
genotype, degree of fibrosis, and associated comorbidities. 
Together, these data indicate the need to establish as a 
national routine the assessment of depression in HCV 
patients, especially those assisted by the Unified Health 
System (SUS), which present socioeconomic frailties and 
limited access to comprehensive care.
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